Orphazyme’s Sorry Story Ends In Fire Sale
KemPharm Acquires Assets For Paltry Sum
Executive Summary
While Orphazyme's attempts to get approval for arimoclomol failed miserably, new owner KemPharm is confident it can get the oral heat shock protein amplifier across the regulatory finishing line for Niemann-Pick disease type C.
You may also be interested in...
End of The Line Looms For Nordic Nanovector
It does not look like the Norwegian biotech can recover from the discontinuation of its lead candidate, the lymphoma drug Betalutin, and the ‘for sale’ signs are likely to be erected soon as a strategic review gets underway.
RhoVac Seeks Path Forward After Phase IIb Prostate Cancer Disappointment
Despite a seemingly sound mechanism and promising early data, the Swedish firm’s sole clinical asset has flunked a mid-stage prostate cancer trial, prompting a search for responsive subgroups.
Finance Watch: Biotech Stocks Stabilize At The End Of A Rocky Week
Public Company Edition: Valuations have fallen enough in 2022 to lead some companies to wind down operations, but a recent uptick opened a window for a few offerings. Chinook raised $105m in a follow-on offering, while Flagship led a $79.2m registered direct offering for Evelo.